Drug Information

Drug General Information
Drug ID
D0OQ5R
Former ID
DIB002298
Drug Name
IGN523
Drug Type
Antibody
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Phase 1 [524608]
Company
Igenica
Target and Pathway
Target(s) Solute carrier family 3 member2 Target Info [533099]
KEGG Pathway Protein digestion and absorption
NetPath Pathway TCR Signaling Pathway
Pathway Interaction Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes
PathWhiz Pathway Kidney Function
Reactome Basigin interactions
Amino acid transport across the plasma membrane
WikiPathways Transport of inorganic cations/anions and amino acids/oligopeptides
Cell surface interactions at the vascular wall
References
Ref 524608ClinicalTrials.gov (NCT02040506) A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML. U.S. National Institutes of Health.
Ref 533099Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015 Aug 1;137(3):710-20.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.